TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05781230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercises Program
Description: HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercises Program
Description: HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercises Program
Description: LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE\>14 indicates high intensity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercises Program
Description: LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE\>14 indicates high intensity
Study: NCT05242042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Study: NCT04983173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian Stimulation with CC+rFSH
Description: : CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian Stimulation with rFSH
Description: rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Study: NCT05322928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in daily occupations
Description: The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life.
Study: NCT04973982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus
Description: 3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoport
Description: 3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
Study: NCT06116136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029
Description: Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg (KEYTRUDA ®)
Description: Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).
Study: NCT05125068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Study: NCT06209008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical injection of Platlet Rich Plasma (PRP)
Description: Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
Study: NCT05361109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
Study: NCT06313450

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: de-escalated radiotherapy
Description: Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with a tumor volume regression of 75% or more and no detectable EBV DNA will receive de-escalated radiotherapy for the primary tumor with 60 Gy. During radiotherapy, patients will receive Cisplatin 100 mg/m2 every three weeks for two courses and Toripalimab 240 mg every three weeks for three courses. If patients do not achieve complete remission at the end of radiotherapy, 6 Gy will be added to the residual lesions.

Intervention type: RADIATION
Group type: OTHER
Intervention: conventional radiotherapy
Description: Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with tumor volume regression less than 75% or EBV DNA copy number higher than 0 receive conventional radiotherapy for the primary tumor with 70 Gy. Patients will receive Cisplatin 100 mg/m2, every three weeks for two courses during radiotherapy.
Study: NCT06306287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePACE Personalized Intervention
Description: The ePACE intervention is based on culturally and developmentally relevant youth treatments organized around an integrative approach based on Motivational Enhancement Therapy (MET) and Cognitive Behavior Therapy (CBT) to enhance motivation for change, support awareness of thoughts, emotions, and behavior, and address specific behavior change goals. The web-based approach is personalized, with youth-driven choices in terms of intensity, content, and sequencing of content and provide tailored feedback to youth regarding each individual's behavior change efforts. Modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Interactive activities, exercises, and quizzes are designed to promote skill acquisition. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eFACE Fixed Intervention
Description: The eFACE intervention includes content that is similar to ePACE, but modules are offered in a fixed order with no tailoring features. Like ePACE, modules address substance use, negative moods, decision-making, and interpersonal relations and require approximately 40-minutes to complete. Each module involves an introduction and engagement strategies, several exercises and activities related to the problem area, goal setting, and a summary. However, no personalized feedback based on youth responses are provided to inform individual youth's behavior change efforts.
Study: NCT04354545

Intervention type: DRUG
Intervention: Xiidra (Lifitegrast ophthalmic solution) 5%
Description: FDA approved lifitegrast opthalmic solution eye drop
Study: NCT05923021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheek acupuncture
Description: Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cheek acupuncture
Description: Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: cheek acupuncture
Description: Cheek acupuncture therapy refers to a new painless acupuncture therapy for treating systemic diseases by acupuncture at specific points on the cheek. This therapy was founded by Professor Wang Yongzhou, a scholar in France. Cheek acupuncture therapy takes the Yellow Emperor's Internal Classic as the theoretical basis, and organically integrates holographic theory, the theory of ascending and descending qi, the theory of Big Three Jiao, the theory of simultaneous treatment of mind and body, and the theory of the book of Changes.In this study, we use the big three jiao points, head points, and neck points in cheek acupuncture therapy to treat depression. These acupoints are considered effective in long-term clinical applications.
Study: NCT04646681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ConnectCare
Description: increased monitoring between clinical mental health visits
Study: NCT06476236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M4C
Description: Nutraceutical designed to enhance novel metabolic pathway activity.
Study: NCT04792567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: taken orally once per day (dose depends on CYP2C9 genotype)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAF312
Description: taken orally once per day (dose depends on CYP2C9 genotype)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline disease modifying therapies (DMTs)
Description: DMTs: Dimethylfumarate, glatirameracetate, interferon, teriflunomode according to respective SmPC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Administerd according to the respective EU SmPC at the discretion of the treating physician independent of AMA-VACC. If suggested by local regulations and performed as part of clinical routine any type of booster/refresher vaccination (e.g. mRNA, vector, peptide) was allowed in this study
Study: NCT05425914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: New treatment option for dry eye patients with low serum vitamin D Level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artificial tear
Description: Conventional dry eye treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial tear
Description: Conventional dry eye treatment
Study: NCT05131984

Intervention type: DRUG
Intervention: Ocrelizumab
Description: At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year

Intervention type: DRUG
Intervention: Ocrelizumab
Description: At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year
Study: NCT06432829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for the transdiagnostic treatment of emotional disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol for the transdiagnostic treatment of emotional disorders
Description: This intervention focuses on a wide range of emotional psychopathology, allowing care for comorbid disorders and subclinical or unspecified symptoms, which reduces treatment times and costs, and improves response to treatment. The intervention will be carried out in an online-group format. For ethical reasons, if any of the patients feel uncomfortable during the study with the online-group format, will may leave the group and receive individual attention. The study plans follow-ups at 1 and 3 months after the end of the treatment.
Study: NCT06471426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The following methods of evaluation and treatment will be utilized on all subjects: Indirect myofascial release to the cervical region, osteopathic cranial manipulation, sacral articular technique.
Study: NCT04822610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene block
Description: peripheral nerve block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprascapular block + axillary block
Description: peripheral nerve block
Study: NCT05718479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Prenatal Intervention (TPI)
Description: TPI is designed to foster behavior change and health coping by enhancing knowledge, beliefs, regulation skills and abilities. In the experimental group, a research staff member will meet with participants and help them to identify a health behavior they want to change, explore the pros and cons of making a change, create a behavior change plan, and learn several mindfulness meditation techniques. The facilitator will check-in with the participants about their behavior change plan in the subsequent sessions regarding progress made, barriers encountered, and changes in the plan and/or goal going forward. Participants will be instructed to implement an at-home mental wellness skills and provided with a tracking log to report the frequency and dose of daily/weekly practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal Education Topics
Description: In the control group, a research staff member will provide participants with four different weekly prenatal education topics, including information on prenatal care, labor and delivery, postpartum care, and newborn care.
Study: NCT04782011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATC/DDD
Description: The intervention is the introduction of the ATC/DDD including the training on its importance and usage in monitoring antibiotic use at a given primary care facility.
Study: NCT05024799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl, propofol
Description: The patients in this group will be administered with fentanyl and propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl and dexmedetomindine
Description: The patients in this group will be administered with fentanyl and dexmedetomindine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol and propofol
Description: The patients in this group will be administered with butorphanol and propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol and dexmedetomindine
Description: The patients in this group will be administered with butorphanol and dexmedetomindine
Study: NCT04869163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-red meat
Description: Red meat analogues and alternatives

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-red meat
Description: Red meat analogues and alternatives
Study: NCT05560282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5.
Study: NCT04666350

Intervention type: OTHER
Intervention: Direct Skin Feeding Assay (DSFA)
Description: In the direct feeding assay a cup with 60 unfed, sterile insectary-reared Anopheles gambiae mosquitoes will be allowed to feed on a participant's calf or arm for 15 minutes.

Intervention type: DRUG
Intervention: Primaquine
Description: Participants will receive one dose of primaquine 26.3 mg tablet on Day 2 after completion of the direct feeding assay.

Intervention type: DRUG
Intervention: Artemether/Lumefantrine
Description: Participants will receive artemether (80 mg) and lumefantrine (480 mg) combination tablets twice a day for 3 days, starting after completion of the direct feeding assay on Day 2.
Study: NCT05800340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 135 mg/m2, d1, 8 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2, d1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, d1 Q3W
Study: NCT05126472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody 2141-V11
Description: Cohort A Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once weekly for 3 doses) at these time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody 2141-V11
Description: Cohort B Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection once every 3 weeks (weeks 1, 4, 7, and 10) for a total of 4 doses. As discussed further below, depending on disease status at week 13 and week 25 evaluations, subjects may be eligible for re-treatment (once every 3 weeks for a total of 4 doses) at these time points.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD40 antibody 2141-V11
Description: Cohort C Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intratumoral injection as a single 10mg during standard of care cystoscopy and examination prior to and within 4 weeks of planned radical cystectomy.
Study: NCT06386965

Intervention type: OTHER
Intervention: taking blood sample
Description: A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.

Intervention type: OTHER
Intervention: taking blood sample
Description: A blood sample will be taken from the patients for 3 times to evaluate the stress inflammatory markers.
Study: NCT06466538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: intracanal medicament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leddermix
Description: Leddermix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boswellia
Description: Boswellia